ClinicalTrials.gg
Not yet recruitingNCT07034040SmaRTWorkUpdated Oct 15, 2026

SmaRTWork - a Decision Support System to Promote Return to Work Among People Sick-listed With Musculoskeletal Disorders

An interventional study of SmaRTWork in Sick Leave and Musculoskeletal, sponsored by Norwegian University of Science and Technology. Not yet recruiting at 1 site in Norway. Open to participants aged 20 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
20 Years to 59 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the effect of an intervention, SmaRTWork, on return to work compared to usual care for individuals who are sick-listed due to musculoskeletal disorders. Potential participants are individuals of working age (20-59 years) sick-listed due to a musculoskeletal disorder (neck pain, low back pain, or widespread pain) for up to 12 weeks living in Norway. The primary outcome will be time to sustainable return to work. We will also evaluate the effect on other work outcomes and health outcomes. We will also interview participants and stakeholders about their experience with the intervention.

Read the detailed description

The objective of this study is to determine the effectiveness of SmaRTWork (intervention) on return to work (RTW) compared to usual care (comparator) for individuals sick-listed due to musculoskeletal disorders. The study is designed as a single-blinded randomised controlled trial (RCT) with two parallel groups. Individuals of working age (20-59 years) sick-listed due to a musculoskeletal disorder (neck pain, low back pain, or widespread pain) for up to 12 weeks living in Norway are eligible for the study. Potential participants are identified and informed about the project by their general practitioner. We plan to include a total of 298 participants in the trial (and 15-20 in a pilot, giving a total of 318). The primary outcome will be time to sustainable RTW, i.e., one month without receiving sickness benefits, during the 12 months of follow-up based on registry data. Secondary outcomes include other work outcomes and health outcomes. Along with the RCT we will also conduct qualitative studies and a process evaluation. If the SmaRTWork turns out to be effective on RTW, we will also perform a health economic evaluation.

02

Conditions studied

  • Sick Leave
  • Musculoskeletal

Keywords

  • Sick leave
  • musculoskeletal disorder
  • sickness absence
  • return to work
  • mHealth
03

In context

Musculoskeletal Diseases

753 studies on the registry are indexed under Musculoskeletal Diseases; 164 are open to participants now.

This study's planned enrollment of 298 is above the median of 76 across 519 interventional studies indexed under Musculoskeletal Diseases.

Browse Musculoskeletal Diseases studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 20-59 years old (working age)
  • Living in Norway
  • Own a smart phone with internet access
  • Sick-listed due to a musculoskeletal disorder for up to 12 weeks
  • The main diagnosis for sick leave is back pain, neck pain or widespread pain. For example one of the following (ICPC-2 diagnoses codes): Neck symptom/complaint (L01), Back symptom/complaint (L02), Low back symptom/complaint (L03), Muscle pain (L18), Back syndrome without radiating pain (L84)

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • No employer (unemployed or self-employed)
  • Poor Norwegian comprehension
  • Sick listed for more than 3 months the previous 12 months
  • Have a planned date for RTW during the next week
  • previous participation in the trial or concurrent participation in another study that could interfere with the current trial
  • Unable to take part in exercise/physical activity (e.g., use of walking aids, unable to get up and down on the floor independently)
  • Leg pain worse than back pain
  • Red flags that could indicate serious underlying pathology:

    • Changes in bladder or bowel function
    • General feeling of being unwell (malaise), fever and/or unexplained weight loss
    • Reduced muscle (motor) function, sensory loss, walking problems or balance problems
    • Neck or back pain that started after the age of 55 or feel different from previous pain episodes
    • Pain that does not improve with rest or light activity or pain that is much worse during the night
    • Previous or ongoing cancer
    • Use of /immune suppressing medications or drug use
    • Pain that is trauma (injury) related
  • Serious ongoing somatic (e.g., unstable heart disease) or mental disorder (e.g., psychosis, ongoing manic episode, suicidal ideation)
  • Pain has not been assessed by a clinician
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
298 participants (estimated)

Study arms

  • Experimental
    SmaRTWork

    This group receives the SmaRTWork intervention in addition to usual care

    Behavioral: SmaRTWork

  • No intervention
    Usual care

    The participants receive usual care as if they were not part of any study. There are no restrictions on what they can or cannot do.

Interventions

  • BehavioralSmaRTWork

    The SmaRTWork app provides weekly individually tailored self-management plans by matching the participant's health information and sick leave status with targeted educational messages, physical activity advice, and exercise recommendations. In addition, participants with specific problems regarding i) work accommodations, ii) workplace conflicts, iii) large responsibilities as caregivers, iv) financial problems, or v) who do not think they will return to the old workplace are offered to be set in contact with a caseworker at the social insurance office. The intervention is given in addition to usual care.

06

What researchers measure

Primary outcomes

  1. Time to sustainable return-to-work (RTW)

    Time to sustainable return-to-work (RTW), i.e., one month without receiving sickness benefits, during the 12 months of follow-up from randomization based on registry data

    Time frame: 12 months from randomization

Secondary outcomes

  1. Number of sickness absence days

    Total number of sickness absence days during 12 months of follow-up from randomization based on registry data

    Time frame: 12 months from randomization

  2. Probability of working each month

    The probability of working (i.e., not receiving medical benefits) each month during 12 months of follow-up, measured as repeated events

    Time frame: 12 months from randomization

  3. Musculoskeletal Health Questionnaire (MSK-HQ)

    Questionnaire that measures musculoskeletal health with scores from 0 to 56 points, with higher scores indicating better musculoskeletal health

    Time frame: From randomization to 12 months of follow-up

  4. Health-related quality of life

    Assessed by the EuroQol 5-dimension questionnaire, weighted according to the Danish value set (range, 0-1, with higher scores indicating better health status) and the EuroQol visual analog scale (range, 0-100, with higher scores indicating better health status)

    Time frame: 12 months from randomization

  5. Average pain last week

    Measured by a numeric rating scale scores from 0 (no pain) to 10 (worst imaginable pain)

    Time frame: 12 months from randomization

  6. Pain Self-Efficacy

    Ability to cope despite pain as assessed with the Pain Self-Efficacy Questionnaire (PSEQ), range, 0-60, with higher scores indicating greater confidence

    Time frame: 12 months from randomization

  7. Depressive symptoms

    Depressive symptoms by the Patient Health Questionnaire-2 (PHQ-2), scores range from 0-6 (higher more symptoms)

    Time frame: 12 months from randomization

  8. Brief Illness Perception

    Cognitive and emotional perceptions of illness assessed by the Brief Illness Perception Questionnaire (range, 0-80, with higher scores indicating greater illness perception)

    Time frame: 12 months from randomization

  9. Work ability

    Work ability measured by the single item from the Work Ability Index (WAI) scored from 0 (worst) to 10 (best).

    Time frame: 12 months from randomization

  10. Overall improvement

    Assessed by the Global Perceived Effect scale. Range, -5 to 5, with positive scores indicating improvement of pain

    Time frame: 12 months from randomization

  11. Fear avoidance beliefs

    Measured by one-item from Tampa Scale of Kinesiophobia scored from 0 (no fear) to 10 (much fear)

    Time frame: 12 months from randomization

  12. Stress

    Measured by the Perceived Stress Scale, scored from 0 to 40, with higher scores indicating greater perceived stress

    Time frame: 12 months from randomization

  13. Insomnia

    Measured by items from the The Trøndelag Health Study (HUNT) populations study. Higher scores worse. Items can be combined to approximate classification of insomnia diagnosis

    Time frame: 12 months from randomization

07

Study locations

1 site
08

References and documents

Publications

  • Aasdahl L, Bach K, Nilsen TIL, Ottersen SG, Klevanger NE, Eder C, Overas CK, Granviken F, Debik J, Lervik LCN, Fossen H, Bones AF, Gismervik S, Hara KW, Mork PJ. Effectiveness of an artificial intelligence-based self-management intervention to support sick-listed individuals with musculoskeletal disorders in Norway: rationale and protocol for the SmaRTWork randomised controlled trial. BMJ Open. 2026 Aug 18;16(8):e122680. doi: 10.1136/bmjopen-2026-122680. PubMed 42613108 ↗

Individual participant data

Plan to share: No — Due to the ethical consent data cannot be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 251 non-industry interventional studies with no phase under Musculoskeletal Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 25 months is above that.

Counting every sponsor, half of 266 studies reached it within 16 months; a quarter within 6 and three quarters within 36.

Musculoskeletal Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jun 24, 2025
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Nov 2026
Oct 15, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42613108 ↗
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42613108 ↗
    Start date Aug 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07034040
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Lene Aasdahl, MD PhD
Contact
lene.aasdahl@ntnu.no
+47 93224342
Paul J Mork, PhD
Contact
paul.mork@ntnu.no
+47 90104615
Lene Aasdahl, MD PhD
principal investigator · Norwegian University of Science and Technology
Solveig K Grudt, Head of Department
study chair · Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion